ClinicalTrials.gg
CompletedNCT01416207Updated Nov 4, 2011

A Multiple-Dose, Open-Label, Phase 1, Pharmacokinetic, Pharmacodynamic, and Safety Study of Avonex® in Chinese Healthy Volunteer Subjects

A Phase 1 interventional study of Avonex in Healthy, sponsored by Biogen. Completed at 1 site in China. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-11-04.

Sponsored by Biogen · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years to 50 Years
Sex
All
01

Study summary

Rationale for the Study:

The purpose of this study is to characterize the pharmacokinetic (PK) and pharmacodynamic (PD) profile of Avonex in Chinese healthy volunteer subjects. Data from this study will be used to support registration of Avonex in China.

Study Design:

This is a multiple-dose, single-arm, open-label, PK/PD and safety study. Four weekly injections of Avonex will be administered intramuscularly (IM). Frequent (intensive) blood samples will be collected with the first and fourth injections of Avonex, and a sparse blood sample will be collected with the second and third injections of Avonex.

Read the detailed description

Rationale for the Study:

The purpose of this study is to characterize the pharmacokinetic (PK) and pharmacodynamic (PD) profile of Avonex in Chinese healthy volunteer subjects. Data from this study will be used to support registration of Avonex in China.

Study Design:

This is a multiple-dose, single-arm, open-label, PK/PD and safety study. Four weekly injections of Avonex will be administered intramuscularly (IM). Frequent (intensive) blood samples will be collected with the first and fourth injections of Avonex, and a sparse blood sample will be collected with the second and third injections of Avonex.

Four Avonex IM injections will be administered in this study. Due to the long-term use of Avonex by MS patients, a multiple-dose PK/PD study is necessary in order to provide adequate information to evaluate changes in drug concentrations over time in Chinese healthy subjects. Serum levels of interferon beta in Caucasian healthy volunteers have been shown to peak between 3 and 15 hours after administration of Avonex IM at the dose being used in this study and have been shown to decline at a rate consistent with a 10-hour elimination half-life; therefore, accumulation of interferon beta following multiple weekly Avonex IM injections is not anticipated.

Exposure of healthy subjects to multiple doses of Avonex in this study is not anticipated to present safety or tolerability issues based on experience from previous Avonex studies that have been conducted in healthy volunteer subjects and MS patients. Flu-like symptoms associated with this dose of Avonex have generally been mostly of mild-to-moderate intensity and of short duration, typically experienced within the first 24 hours after injection. Prophylactic analgesic medication must be administered prior to each Avonex injection during the study which is a recommended practice with the use of interferon therapies in order to ameliorate flu-like symptoms.

Study Location:

China, at 1 Phase 1 study site.

Duration of Treatment and Follow-up:

Approximately 2 months, including a 28-day Screening and Baseline period, a 3-week Treatment and blood sampling period and a 14-day Follow-Up period.

Statistical Methods:

PK/PD parameters will be calculated using non-compartmental methods. Summary statistics for each PK/PD parameter will be calculated. Mean concentration values will be plotted over time both on a linear and a logarithmic scale.

The incidence of treatment-emergent AEs will be summarized. Vital signs will be examined to determine the incidence of clinically relevant abnormalities.

Laboratory evaluations will be assessed to determine the incidence of abnormalities. Changes in laboratory evaluations will be summarized using shift tables and summary statistics.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Biogen is the lead sponsor of 512 studies on the registry; 25 are open to participants now.

Of its 100 completed or terminated interventional studies of FDA-regulated products, 50 (50%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ability to understand the purpose and risks of the study and provide signed and dated and authorization to use protected health information (PHI) in accordance with national and local subject privacy regulations.
  • Subjects of Chinese origin (at least both maternal and paternal grandparents of Chinese origin).
  • (BMI) within the range of 18.5 to 30 kg/m2 (inclusive).
  • All male subjects and female subjects of must practice effective during the study and be willing and able to continue contraception for 30 days after their last dose of study treatment.

Exclusion criteria

Exclusion Criteria:

  • History of seizure disorder or unexplained blackouts OR history of a seizure within 6 months prior to Day 1.
  • History of suicidal ideation or an episode of clinically severe depression (as determined by the Investigator) within 6 months prior to Day 1.
  • Any presence (as determined by the Investigator) of cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, or other major disease.
  • Positive test result for antibody (HCV Ab), or current infection at Screening.
  • Known history of (HIV).
  • Clinically significant abnormal laboratory values.
  • History of alcohol abuse (as defined by the Investigator), or a positive blood screen test for presence for alcohol at Screening.
  • History of drug abuse (as defined by the Investigator), or a positive urinary screen test for presence of cocaine and morphine.
  • Premalignant and malignant disease.
  • History of clinically significant severe allergic or anaphylactic reactions.
  • Known allergy to any component of the Avonex formulation.
  • History of or intolerance to prophylactic analgesic medication that would preclude use during the study.
  • Clinically significant abnormal (ECG) values as determined by the Investigator.
  • Known allergy to interferon beta-1a.
  • Active bacterial or viral infection.
  • Female subjects who are pregnant or currently breastfeeding.
  • Previous participation in another drug study within the last 1 month or 7 half-lives, whichever is longer, or previous participation in this study.
  • Treatment with any prescription medication within 14 days of Day 1.
  • Treatment with any over-the-counter products within the 14 days prior to Day 1.
  • Donation of blood (500 mL or greater) within 56 days prior to Day 1.
  • Inability to comply with study requirements
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Avonex

    4 weekly injections of Avonex (IM)

    Drug: Avonex

Interventions

  • DrugAvonex

    4 weekly injections of Avonex (IM)

    Also known as: Interferon-β1a

06

What researchers measure

Primary outcomes

  1. Cmax

    Time frame: Participants will be followed for the duration of the study; and expected 2 months

  2. Tmax

    Time frame: Participants will be followed for the duration of the study; and expected 2 months

  3. AUC 0-t

    Time frame: Participants will be followed for the duration of the study; and expected 2 months

  4. AUC 0-infinity

    Time frame: Participants will be followed for the duration of the study; and expected 2 months

  5. T 1/2

    Time frame: Participants will be followed for the duration of the study; and expected 2 months

  6. Tlag

    Time frame: Participants will be followed for the duration of the study; and expected 2 months

  7. Ka

    Time frame: Participants will be followed for the duration of the study; and expected 2 months

  8. T 1/2ab

    Time frame: Participants will be followed for the duration of the study; and expected 2 months

  9. Kcl

    Time frame: Participants will be followed for the duration of the study; and expected 2 months

  10. Kir

    Time frame: Participants will be followed for the duration of the study; and expected 2 months

  11. Emax

    Time frame: Participants will be followed for the duration of the study; and expected 2 months

  12. Tmax(E)

    Time frame: Participants will be followed for the duration of the study; and expected 2 months

  13. Eauc

    Time frame: Participants will be followed for the duration of the study; and expected 2 months

  14. Induction ratio

    Time frame: Participants will be followed for the duration of the study; and expected 2 months

  15. T1/2 return to baseline

    Time frame: Participants will be followed for the duration of the study; and expected 2 months

Secondary outcomes

  1. Number of Adverse Events as a measure of safety and tolerability

    Time frame: Participants will be followed for the duration of the study; and expected 2 months

  2. Number of Serious Adverse Events as a measure of safety and tolerability

    Time frame: Participants will be followed for the duration of the study; and expected 2 months

  3. Changes in lab assessments

    Time frame: Participants will be followed for the duration of the study; and expected 2 months

  4. Changes in vital signs

    Time frame: Participants will be followed for the duration of the study; and expected 2 months

  5. Changes in physical examinations

    Time frame: Participants will be followed for the duration of the study; and expected 2 months

  6. Changes in ECGs

    Time frame: Participants will be followed for the duration of the study; and expected 2 months

07

Study locations

1 site
  • Research Site
    Shanghai, China
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2011, a primary completion of Oct 2011 and a completion of Oct 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2011
First posted
Aug 12, 2011
Start
Aug 2011
Primary completionActual
Oct 2011
CompletionActual
Oct 2011
Last update
Nov 4, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 4, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01416207
Lead sponsor
Biogen
First posted
Aug 12, 2011
Start date
Aug 2011
Primary completion
Oct 2011
Completion
Oct 2011
Last update
Nov 4, 2011

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Interferon beta-1a

Start the discussion